SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Amylyx Pharmaceuticals, Inc. (AMLX) has a negative trailing P/E of -11.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 24.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -9.11%, forward earnings yield 4.08%. PEG 0.12 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (78/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.12); analyst target implies upside (+30%).
- Forward P/E 24.5 — analysts expect a return to profitability with estimated EPS of $0.69 for FY2029.
- PEG Ratio 0.12 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -9.11% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 4.08% as earnings recover.
- Analyst consensus target $22.00 (+30% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 60/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
78/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AMLX
Valuation Multiples
P/E (TTM)-11.0
Forward P/E24.5
PEG Ratio0.12
Forward PEG0.12
P/B Ratio5.20
P/S Ratio0.00
EV/EBITDA-8.2
Per Share Data
EPS (TTM)$-1.53
Forward EPS (Est.)$0.69
Book Value / Share$3.23
Revenue / Share$0.00
FCF / Share$-1.31
Yields & Fair Value
Earnings Yield-9.11%
Forward Earnings Yield4.08%
Dividend Yield0.00%
Analyst Target$22.00 (+30%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-68.9 |
0.00 |
-40.24 |
715.53 |
- |
| 2020 |
-24.1 |
-0.12 |
-15.29 |
1,569.76 |
- |
| 2021 |
-11.9 |
-0.13 |
-6.92 |
0.00 |
- |
| 2022 |
-12.4 |
-0.13 |
7.22 |
110.55 |
- |
| 2023 |
20.1 |
-0.16 |
2.28 |
2.60 |
- |
| 2024 |
-0.9 |
0.00 |
1.56 |
2.95 |
- |
| 2025 |
-7.9 |
0.12 |
3.74 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.26 |
$1.43M |
$-14.82M |
-1039% |
| 2020 |
$-0.79 |
$650K |
$-44.84M |
-6898% |
| 2021 |
$-1.52 |
$285K |
$-87.88M |
-30834.7% |
| 2022 |
$-2.98 |
$22.23M |
$-198.38M |
-892.4% |
| 2023 |
$0.70 |
$380.79M |
$49.27M |
12.9% |
| 2024 |
$-4.43 |
$87.37M |
$-301.74M |
-345.4% |
| 2025 |
$-1.53 |
$0.00 |
$-144.74M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-1.35 |
$-1.60 – $-0.85 |
$80.63K |
$31.68K – $131.43K |
7 |
| 2027 |
$-1.24 |
$-1.83 – $-0.41 |
$44.68M |
$16.87M – $73.55M |
7 |
| 2028 |
$-0.57 |
$-1.04 – $0.23 |
$153.25M |
$153.25M – $153.25M |
6 |
| 2029 |
$0.69 |
$0.15 – $1.26 |
$321.42M |
$126.28M – $523.96M |
4 |
| 2030 |
$2.07 |
$0.44 – $3.76 |
$538.31M |
$211.5M – $877.53M |
2 |
